The supplemental new drug application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) has been accepted and filed by the ...
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Otsuka Pharmaceutical Co Ltd (OTC: OTSKF) (OTC: OTSKY) (Otsuka) and H. Lundbeck A/S have received FDA approval for Rexulti (brexpiprazole) for use in the treatment of agitation associated with ...
Scientists have developed the first validated green reversed-phase HPLC method that simultaneously and accurately measures brexpiprazole and escitalopram oxalate in a combined formulation while ...
Brexpiprazole was approved in the U.S. on July 10, 2015, as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment for schizophrenia in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results